Month: January 2021

HOUSTON, Jan. 29, 2021 (GLOBE NEWSWIRE) — Recruiter.com (OTCQB:RCRT) released its January 2021 Shareholder Letter highlighting its 2020 accomplishments and outlining its plans to achieve $40M in run-rate revenue along with profitability.“Our corporate mission aligns with our nation’s mission at this historic moment. As the country seeks to rebuild in the aftermath of the pandemic, we will drive the effort to re-hire millions of people and provide new economic opportunities for the next generation,” said Evan Sohn, CEO of Recruiter.com. “As a destination website for all things recruiting (last month, we generated $4M in organic [free] traffic according to SpyFu.com), we believe Recruiter.com is uniquely positioned to generate significant revenue by helping employers, candidates, and recruiters make meaningful employment connections....

TORONTO, Jan. 29, 2021 (GLOBE NEWSWIRE) — Decklar Resources Inc. (DKL-TSX Venture) (the “Company”) is pleased to provide an update to previously announced funding arrangements by its wholly-owned Nigeria-based subsidiary, Decklar Petroleum Limited, to develop the Oza Oil Field in Nigeria. When fully disbursed, these funds are expected to be sufficient to re-establish oil production and provide development funding for the Company’s Oza Oil Field. The details of the funding plans are included in the Company’s August 31, 2020 press release.Update Regarding Funding ArrangementsThe due diligence required to finalize the term debt arranged with a Nigerian bank and the trading subsidiary of a large multinational oil company active in Nigeria has progressed, and the final report by the independent technical consultant they contracted and...

Un exercice 2020 fortement impacté par les effets de la crise sanitaire, mais aussi marqué par :Le lancement opérationnel et l’intérêt soutenu pour la solution Mini-P2R avec la signature de 3 LOI et la mise en construction de la première unitéLe maintien du calendrier de démarrage de notre unité de MarseilleLa forte progression de notre performance RSE récompensée par notre nouvelle notation Gaïa Rating et notre intégration au label « Solar Impulse Efficient Solution »Paris, le 29 janvier 2021Aussi, l’unité de Sines au Portugal a dû être arrêtée durant 37 jours (du 18 avril au 15 mai) représentant un manque à gagner en terme de production de plus de 3.000 tonnes.  La production de produits raffinés par l’unité de Sinès s’est élevée en 2020 à 21.600 tonnes (contre 25.800 tonnes en 2019), soit une baisse de 16%.* : données non auditéesLa...

DENVER, CO, Jan. 29, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — The Stock Day Podcast welcomed American Cannabis Company, Inc. (OTCQB: AMMJ) (“the Company”), a company that offers end-to-end solutions to existing and aspiring participants in the cannabis and hemp industries. CEO of the Company, Terry Buffalo, joined Stock Day host Everett Jolly.Jolly commented on the Company’s impressive growth over the last year, and asked about their background and current projects. “American Cannabis Company has been around since 2013,” shared Buffalo. “The company has built out over 2 million square feet of growth space, and along the way we have been looking to add additional products and services, which we have with SoHum Living Soils®,” he continued. “We’re currently looking to make...

COMMACK, NY, Jan. 29, 2021 (GLOBE NEWSWIRE) —  via NewMediaWire — Patient Access Solutions, Inc. (OTC PINK: PASO), a provider of technology and management solutions for the healthcare and financial industries, has announced today that Patient Access Solutions, (PASO) Hestia Insight through its subsidiary Hestia Health, and US Stem Cell will form a Consortium business model for the treatment of individuals with anxiety and depression. Anxiety disorders affect 40 million adults and one in eight children in the United States. They interfere with daily functioning and often lead to depression, substance abuse, suicide attempts and other disorders. Depressive disorders affect about 19 million American adults. More than 50 percent of people diagnosed with depression also have an anxiety disorder. Coexisting anxiety and depression...

RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES Milan, 29 January 2021 – Recordati announces the closing of a License and Supply Agreement with Tolmar International Ltd, to commercialise Eligard® (leuprorelin acetate), in Europe, Turkey, Russia and other countries. Eligard® is a marketed medicinal product for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.  The active ingredient of Eligard® is leuprorelin acetate, a powder which is solubilized with a solvent for subcutaneous injection. Eligard® is available in three different dosages (for 1-month, 3-month and 6-month treatment, respectively) as a single kit containing two syringes. The development...

RECORDATI: OTTENUTA LICENZA PER LA COMMERCIALIZZAZIONE DI ELIGARD® IN EUROPA E ALTRI PAESIMilano, 29 gennaio 2021 – Recordati annuncia il perfezionamento di un accordo di Licenza e Fornitura con Tolmar International Ltd, per la commercializzazione di Eligard® (leuprorelin acetato), in Europa, Turchia, Russia e altri paesi. Eligard® è un medicinale indicato per il trattamento del cancro della prostata ormono-dipendente in stadio avanzato e per il trattamento del cancro della prostata ormono-dipendente ad alto rischio localizzato e localmente avanzato, in combinazione con la radioterapia.Il principio attivo di Eligard®, leuprorelin acetato, si presenta sottoforma di una polvere che viene solubilizzata con un solvente per iniezione sottocutanea. Eligard® è disponibile in tre diversi dosaggi (rispettivamente per 1 mese, 3 mesi e 6 mesi...

Company AnnouncementNovartis receives positive CHMP opinion for subcutaneous ofatumumab for adult patients with relapsing forms of multiple sclerosisOpinion based on Phase 3 ASCLEPIOS I and II studiesCopenhagen, Denmark; January 28, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization of subcutaneous ofatumumab for the treatment of relapsing forms of multiple sclerosis (RMS) in adults with active disease defined by clinical or imaging features. Novartis submitted the Marketing Authorization Application for ofatumumab in this indication in January 2020. Ofatumumab is being developed and marketed worldwide by Novartis under a license agreement between Genmab and...

 Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS1CHMP opinion is based on two Phase III ASCLEPIOS studies that met the primary endpoints where Kesimpta showed a reduction of the annual relapses by over 50% versus teriflunomide and achieved more than 30% relative risk reduction of 3-month confirmed disability progression (CDP) 1In a post hoc analysis, nearly nine out of 10 patients treated with Kesimpta achieved no evidence of disease activity (NEDA-3) in their second year of treatment2If approved, Kesimpta will be the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis in EuropeThe digital press release with multimedia content can be accessed here:Basel, January...